Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + trametinib versus dabrafenib + placebo in first-line BRAF V600E/K-mutant advanced cutaneous melanoma
2011-006087-49Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) comparing Dabrafenib + trametinib with Dabrafenib + placebo (2 arms). Primary endpoint: Progression-free survival. Started Mar 2012; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2011-006087-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006087-49.